36725-28-7: Levosimendan Inhouse Impurity

Status: In-stock

It is an impurity present in Levosimendan, Levosimendan increases myofilament calcium sensitivity by binding to cardiac troponin C in a calcium-dependent manner. by stabilizing the calcium-induced conformational change of troponin C by changing actin-myosin. cross-bridge kinetics apparently without increasing the cycling rate of the cross bridges increasing the effects of calcium on cardiac myofilaments during systole, also have a selective phosphodiesterase (PDE)-III inhibitory action. levosimendan acts preferentially as a Ca2+ sensitizer at lower concentrations whereas at higher concentrations its action as a PDE-III inhibitor becomes more prominent in experimental animals and humans.

Additional information on CAS 36725-28-7

Catalogue No. VE006147
CAS No. 36725-28-7
Molecular Formula C11H13N3O
Molecular Weight 203.24 g/mol
Parent drug Levosimendan
IUPAC Name 6-(4-Aminophenyl)-4, 5-dihydro-5-methyl-3(2H)-pyridazinone
Synonyms 6-(4-Aminophenyl)-4, 5-dihydro-5-methyl-3(2H)-pyridazinone; 6-(p-Aminophenyl)-5-methyl-4, 5-dihydro-3(2H)-pyridazinone; SKF 93505;
References Nieminen, M. S., Fruhwald, S., Heunks, L. M. A., Suominen, P. K., Gordon, A. C., Kivikko, M., & Pollesello, P. (2013). Levosimendan: current data, clinical use and future development. Heart, Lung and Vessels, 5(4), 227–245. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868185/
Status In-stock

Request a quote

We Respond Within a Few Hours - Whether You're a New or Existing Client

Payment Made Simple: All major Credit/Debit cards accepted

Streamlined 3-Step Process from Quotes to Orders:

Product name:

36725-28-7: Levosimendan Inhouse Impurity

"*" indicates required fields

Products quotation
This field is for validation purposes and should be left unchanged.